Search results
ESG More Cost-Effective Long Term Than Semaglutide
Medscape· 2 weeks agoSemaglutide is an effective treatment option for weight loss, but its cost-effectiveness over the long term compared with ESG needs to be considered.
Reimbursement limited for popular diabetes medication
China Daily· 18 hours agoA popular weight loss medication approved for the treatment of diabetes was added to China's national drug reimbursement list in 2022, but coverage will be limited to diabetes patients, the ...
Surgery May Be More Cost-Effective Than Wegovy in Adults With a BMI 35+
MedPage Today· 2 weeks agoTo be on par with sleeve gastroplasty in terms of cost-effectiveness over a 5-year span, the annual ...
Best Ozempic Alternatives – Most Popular Semaglutide Injection Substitutes for Natural Diabetes...
Greeley Tribune· 2 weeks agoAre you or someone you know managing type 2 diabetes? Keeping blood sugar levels stable is essential...
American College Of Physicians Officially Recommends GLP-1s Like Ozempic For Diabetes...
Forbes· 4 days agoThe American College of Physicians issued new guidelines for Type 2 diabetes treatment, which for...
BMO Capital starts Novo Nordisk at Outperform By Investing.com
Investing.com· 2 weeks agoOn Friday, BMO Capital initiated coverage of Novo Nordisk (NYSE:NVO) with an Outperform rating and a...
Popular weight loss drugs in tight supply as Zepbound shortage could last through June
ABC News· 3 days agoShortages of popular weight loss medications are continuing amid an all-time high of drug scarcity...
New Weight-Loss Drugs Are Meant to Be Lifelong. What Happens When You Quit?
Scientific American· 4 days agoWegovy, Ozempic and similar weight-loss drugs have become some of the most popular medications in...
Is Eli Lilly Stock A Buy After Weight-Loss Drug Succeeds In Sleep Apnea Patients?
Investor's Business Daily· 5 days agoTirzepatide currently sells as a diabetes shot called Mounjaro and in weight loss as Zepbound. Its...
Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European...
Benzinga· 2 weeks agoThe European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has determined that there is no substantial evidence supporting a link between Glucagon-Like Peptide-1 receptor ...